Skip to main content

Acurx Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

ACXP$1.060.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**

​ACURX PHARMACEUTICALS, INC.
Date: March 12, 2026By:/s/ David P. Luci
​​David P. Luci
​​President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Signature​ ​ ​Title​ ​ ​Date
​​​​​
/s/ David P. Luci​President, Chief Executive Officer and Director​March 12, 2026
David P. Luci(Principal Executive Officer)
​​​​​
/s/ Robert G. Shawah​Chief Financial Officer​March 12, 2026
Robert G. Shawah(Principal Accounting Officer and Principal Financial Officer)
​​​​​
/s/ Robert J. DeLuccia​Executive Chairman​March 12, 2026
Robert J. DeLuccia​​​
​​​​​
/s/ Carl V. Sailer​Director​March 12, 2026
Carl V. Sailer​​​
​​​​​
/s/ Joseph C. Scodari​Director​March 12, 2026
Joseph C. Scodari​​​
​​​​​
/s/ Thomas Harrison​Director​March 12, 2026
Thomas Harrison​​​
​​​​​
/s/ Jack H. Dean​Director​March 12, 2026
Jack H. Dean​​​
​​​​​
/s/ James Donohue​Director​March 12, 2026
James Donohue​​​

INDEX TO FINANCIAL STATEMENTS

Years Ended December 31, 2025 and 2024​ ​ ​Page
Report of Independent Registered Public Accounting Firm (PCAOB ID: 596)​F-2
Balance Sheets​F-3
Statements of Operations​F-4
Statements of Changes in Shareholders’ Equity​F-5
Statements of Cash Flows​F-6
Notes to Financial Statements​F-7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.